Statement: poems syndrome is a syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.  it is often associated with osteosclerotic myeloma. the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease .
Primary_evidence: Outcome Measurement:    Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.   The trial was designed as a single-stage phase II rather then usual two-stage design because of the progression free survival (PFS) primary endpoint, as it is impractical to wait to assess PFS for patients in the first stage. We will consider a PFS of 50% at twelve months (median PFS of 12 months) or less uninteresting and a PFS of 70% at twelve months (median PFS of twenty months) worthy of pursuing the regimen in a future trials. The single-stage design is as follows: p0=0.50, p1=0.70, α=0.10, β= 0.10. This leads to a total sample size of 39 patients, 24 or higher of who are progression-free at 12 months.   Time frame: up to 3 years Results 1:    Arm/Group Title: Trastuzumab, Bevacizumab, and Docetaxel   Arm/Group Description: Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M ]   Overall Number of Participants Analyzed: 26   Median (95% Confidence Interval)   Unit of Measure: months  14.3        (9.3 to 35)